Alnylam Pharmaceuticals, Inc.

GIVLAARI

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

Alnylam Pharmaceuticals, Inc.

Givlaari HCPCS:

J0223

HCPCS Code Descriptor:

Injection, givosiran, 0.5 mg

Category:

J Code

Givlaari NDCs:

71336-1001-01

Primary Type:

Genetic Disorder

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Subcutaneous

Givlaari CPT Codes:

Potential CPT administration codes for Givlaari can be found at the following link.

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Givlaari:

GIVLAARI is a Genetic Disorder drug manufactured by Alnylam Pharmaceuticals, Inc. and administered via the Subcutaneous route of administration. The J Code: J0223 is aligned to the drug GIVLAARI.

ACCESS PRICING AND MORE BY REGISTERING

J0223 Added Date:

July 1, 2020

J0223 Effective Date:

July 1, 2020

J0223 Termination Date:

HCPCS Active

Givlaari billing and coding information can be found through Alnylam Pharmaceuticals, Inc. at the link below:
Givlaari patient assistance information can be found through Alnylam Assist at the URL: https://www.alnylamassist.com/
GIVLAARI prescribing information can be found at the link below:
Our team has not yet identified a source of side effects information for GIVLAARI. Please check back in a few weeks.